PE20010230A1 - Sulfonamidas como inhibidores de aspartil proteasa - Google Patents
Sulfonamidas como inhibidores de aspartil proteasaInfo
- Publication number
- PE20010230A1 PE20010230A1 PE2000000573A PE0005732000A PE20010230A1 PE 20010230 A1 PE20010230 A1 PE 20010230A1 PE 2000000573 A PE2000000573 A PE 2000000573A PE 0005732000 A PE0005732000 A PE 0005732000A PE 20010230 A1 PE20010230 A1 PE 20010230A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- aspartile
- heterocycle
- cycloalkyl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Abstract
SE REFIERE A UN COMPUESTO SULFONAMIDA DE FORMULA I, DONDE: A ES H, Ht, R1-Ht, R1-ALQUILO C1-C6; R1 ES -C(O)-, S(O)2, -C(O)-C(O)-, -O-C(O)-, O-S(O)2, ENTRE OTROS; Ht ES CICLOALQUILO C3-C7, CICLOALQUENILO C5-C7, ARILO C6-C14, HETEROCICLO C5-C7 QUE CONTIENE N, N(R2), O, S, S(O)n, DICHO ARILO O HETEROCICLO ESTA FUSIONADO A Q; R2 ES H, ALQUILO C1-C4 OPCIONALMENTE SUSTITUIDO CON UN ANILLO CARBOXICLICO DE 3 A 7 MIEMBROS, HETEROCICLO DE 5-7 MIEMBROS OPCIONALMENTE SUSTITUIDO CON 1-4 -X`-Y', O-ARILALQUILO, ENTRE OTROS; X' ES O, S, NH, NHCO, NHCOO, ENTRE OTROS; Y' ES ALQUILO C1-C15, ALQUENILO C2-C15; G ES H, R7, ALQUILO C1-C4; CUANDO G ES ALQUILO C1-C4, G Y R7 ESTAN UNIDOS Y FORMAN UN ANILLO HETEROCICLO; D ES ALQUILO C1-C6 SUSTITUIDO CON Q OPCIONALMENTE SUSTITUIDO CON CICLOALQUILO C3-C6, ENTRE OTROS; E ES Ht, O-Ht, ALQUILO C1-C6, ENTRE OTROS; R7 ES GRUPO a, b; M ES Na, Mg, ENTRE OTROS; M' ES H, ALQUILO C1-C12, ALQUENILO C2-C12, ENTRE OTROS; x ES 0-1; y ES P, S; X ES O, S; Z ES O, S, N(R2)2. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE ADEMAS (1O,2ß,3O)-9-[2,3-BIS(HIDROXIMETIL)CICLOBUTIL]GUANINA, NUCLEOSIDOS ACICLICOS, ACICLOVIR, LAMIVUDINA, RIBAVIRINA, INTERFERON, ENTRE OTROS. EL COMPUESTO I INHIBE A LA ASPARTIL PROTEASA HIVY PUEDE SER UTIL PARA EL TRATAMIENTO DEL SIDA, LINFADENOPATIA PROGRESIVA GENERALIZADA, SARCOMA DE KAPOSI
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13907099P | 1999-06-11 | 1999-06-11 | |
US19021100P | 2000-03-17 | 2000-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20010230A1 true PE20010230A1 (es) | 2001-03-15 |
Family
ID=26836833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2000000573A PE20010230A1 (es) | 1999-06-11 | 2000-06-08 | Sulfonamidas como inhibidores de aspartil proteasa |
Country Status (31)
Country | Link |
---|---|
EP (2) | EP1194404B1 (es) |
JP (2) | JP4503896B2 (es) |
KR (1) | KR100762188B1 (es) |
CN (2) | CN101245058A (es) |
AR (1) | AR031520A1 (es) |
AT (2) | ATE534622T1 (es) |
AU (1) | AU779994B2 (es) |
BR (1) | BR0011745A (es) |
CA (1) | CA2380858C (es) |
CO (1) | CO5160337A1 (es) |
CY (1) | CY1112632T1 (es) |
CZ (1) | CZ303052B6 (es) |
DE (1) | DE60027722T2 (es) |
DK (2) | DK1194404T3 (es) |
ES (2) | ES2375823T3 (es) |
HK (1) | HK1046899B (es) |
HU (1) | HUP0300385A3 (es) |
IL (3) | IL146918A0 (es) |
MX (1) | MXPA01012808A (es) |
MY (1) | MY137777A (es) |
NO (1) | NO323951B1 (es) |
NZ (1) | NZ516003A (es) |
PE (1) | PE20010230A1 (es) |
PL (1) | PL210227B1 (es) |
PT (2) | PT1686113E (es) |
SI (1) | SI1194404T1 (es) |
TN (1) | TNSN00129A1 (es) |
TR (3) | TR200200407T2 (es) |
TW (3) | TW593248B (es) |
WO (1) | WO2000076961A1 (es) |
ZA (1) | ZA200110177B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU767728B2 (en) * | 1998-06-19 | 2003-11-20 | Vertex Pharmaceuticals Incorporated | Sulfonamide inhibitors of aspartyl protease |
AR031520A1 (es) * | 1999-06-11 | 2003-09-24 | Vertex Pharma | Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion |
DK1370543T3 (da) | 2001-02-14 | 2007-02-19 | Tibotec Pharm Ltd | Bredspektrede 2-(substitueret amino) benzothiazol- sulfonamid-HIV-proteaseinhibitorer |
US7285566B2 (en) * | 2002-01-07 | 2007-10-23 | Erickson John W | Resistance-repellent retroviral protease inhibitors |
MY142238A (en) | 2002-03-12 | 2010-11-15 | Tibotec Pharm Ltd | Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors |
DE60315023T2 (de) * | 2002-04-26 | 2008-04-03 | Gilead Sciences, Inc., Foster City | Anreicherung in der zelle an phosphonat analoga von hiv protease inhibitor verbindungen und die verbindungen selbst |
US6632816B1 (en) * | 2002-12-23 | 2003-10-14 | Pharmacor Inc. | Aromatic derivatives as HIV aspartyl protease inhibitors |
US20060148865A1 (en) * | 2003-06-27 | 2006-07-06 | Martin Michael T | Preparation of chemical compounds |
NZ575575A (en) | 2003-08-18 | 2010-04-30 | Lundbeck & Co As H | Succinate and malonate salt of trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament |
CN101671307B (zh) * | 2003-12-15 | 2014-05-14 | 默沙东公司 | 杂环天冬氨酰蛋白酶抑制剂 |
AU2005222435B2 (en) | 2004-03-11 | 2012-03-15 | Sequoia Pharmaceuticals, Inc. | Resistance-repellent retroviral protease inhibitors |
TWI383975B (zh) | 2004-03-31 | 2013-02-01 | Tibotec Pharm Ltd | 製備(3R,3aS,6aR)六氫-呋喃并〔2,3-b〕呋喃-3-醇之方法 |
US7388008B2 (en) | 2004-08-02 | 2008-06-17 | Ambrilia Biopharma Inc. | Lysine based compounds |
TWI376373B (en) | 2005-02-16 | 2012-11-11 | Lundbeck & Co As H | Crystalline base of a pharmaceutical compound |
TWI453198B (zh) | 2005-02-16 | 2014-09-21 | Lundbeck & Co As H | 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s)-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法 |
US20080194554A1 (en) * | 2005-03-11 | 2008-08-14 | Mclean Ed W | Hiv Protease Inhibitors |
EP1971615B1 (en) | 2005-11-30 | 2014-01-01 | TaiMed Biologics, Inc. | Lysme-based prodrugs of aspartyl protease inhibitors and processes for their preparation |
JP2009544708A (ja) * | 2006-07-24 | 2009-12-17 | ギリアード サイエンシーズ, インコーポレイテッド | ビスフラニルプロテアーゼ阻害剤 |
BRPI0718706B8 (pt) | 2006-11-09 | 2021-05-25 | Janssen R & D Ireland | métodos para a preparação de hexa-hidrofuro[2,3- b]furan-3-ol |
EP2491785A1 (en) * | 2006-11-21 | 2012-08-29 | Purdue Research Foundation | Method and compositions for treating HIV infections |
ATE498606T1 (de) | 2007-04-27 | 2011-03-15 | Tibotec Pharm Ltd | Herstellungsverfahren für n-isobutyl-n-(2-hydroxy-3-amino-4-phenylbutyl)- - nitrobenzolsulfonylamidderivate |
GB2452952A (en) * | 2007-09-20 | 2009-03-25 | Npil Pharmaceuticals | N-[2-Hydroxy-3-(hydroxycarbonylamino)-3-methyl]-N-methyl-sulphonamide derivatives via N-[2-oxo-3-(hydroxycarbonylamino)-3-methyl]-N-methyl-imine skeleton |
US8592487B2 (en) | 2007-10-26 | 2013-11-26 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
DK2480220T3 (en) * | 2009-09-22 | 2015-02-23 | Janssen R & D Ireland | Treatment and prevention of HIV infection |
WO2011061590A1 (en) | 2009-11-17 | 2011-05-26 | Hetero Research Foundation | Novel carboxamide derivatives as hiv inhibitors |
CN103193570B (zh) * | 2013-04-09 | 2014-01-22 | 湖北来凤腾升香料化工有限公司 | 一种羟基高选择性保护方法 |
JPWO2016039403A1 (ja) * | 2014-09-11 | 2017-06-29 | 塩野義製薬株式会社 | 持続性hivプロテアーゼ阻害剤 |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3635907A1 (de) * | 1986-10-22 | 1988-04-28 | Merck Patent Gmbh | Hydroxy-aminosaeurederivate |
CA2032259A1 (en) * | 1989-12-18 | 1991-06-19 | Wayne J. Thompson | Hiv protease inhibitors useful for the treatment of aids |
EP0813868B1 (en) * | 1990-11-19 | 2005-06-01 | Monsanto Company | Retroviral protease inhibitors |
US5475013A (en) * | 1990-11-19 | 1995-12-12 | Monsanto Company | Retroviral protease inhibitors |
KR100336699B1 (ko) * | 1992-08-25 | 2002-05-13 | 윌리암스 로저 에이 | 레트로바이러스 프로테아제 저해제로서 유용한히드록시에틸아미노 술폰아미드 |
US5723490A (en) * | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
EP0666843B1 (en) * | 1992-10-30 | 1999-08-18 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfamic acids useful as retroviral protease inhibitors |
DE69415326T2 (de) * | 1993-08-24 | 1999-06-02 | Searle & Co | Hydroxyaminosulfonamide verwendbar als inhibitoren retroviraler proteasen |
DE69637380T2 (de) * | 1995-01-20 | 2009-09-17 | G.D. Searle Llc, Chicago | Bis-sulfonamid-hydroxyethylamino-derivate als inhibitoren retroviraler proteasen |
US5756533A (en) * | 1995-03-10 | 1998-05-26 | G.D. Searle & Co. | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US6150556A (en) * | 1995-03-10 | 2000-11-21 | G. D. Dearle & Co. | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
WO1996028465A1 (en) * | 1995-03-10 | 1996-09-19 | G.D. Searle & Co. | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US5705500A (en) * | 1995-03-10 | 1998-01-06 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
US5691372A (en) * | 1995-04-19 | 1997-11-25 | Vertex Pharmaceuticals Incorporated | Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease |
WO1997018205A1 (en) * | 1995-11-15 | 1997-05-22 | G.D. Searle & Co. | Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
GB9712504D0 (en) * | 1997-06-17 | 1997-08-20 | Dundee Teaching Hospitals Nhs | Thermal imaging method and apparatus |
WO1999010373A1 (en) * | 1997-08-26 | 1999-03-04 | Wisconsin Alumni Research Foundation | Non-immunosuppressive cyclosporins and their use in the prevention and treatment of hiv infection |
AR031520A1 (es) * | 1999-06-11 | 2003-09-24 | Vertex Pharma | Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion |
-
2000
- 2000-06-07 AR ARP000102852A patent/AR031520A1/es active IP Right Grant
- 2000-06-08 DK DK00941279T patent/DK1194404T3/da active
- 2000-06-08 PE PE2000000573A patent/PE20010230A1/es not_active Application Discontinuation
- 2000-06-08 WO PCT/US2000/015781 patent/WO2000076961A1/en active Application Filing
- 2000-06-08 TW TW089111145A patent/TW593248B/zh not_active IP Right Cessation
- 2000-06-08 CA CA2380858A patent/CA2380858C/en not_active Expired - Fee Related
- 2000-06-08 JP JP2001503821A patent/JP4503896B2/ja not_active Expired - Fee Related
- 2000-06-08 PL PL352830A patent/PL210227B1/pl not_active IP Right Cessation
- 2000-06-08 TR TR2002/00407T patent/TR200200407T2/xx unknown
- 2000-06-08 EP EP00941279A patent/EP1194404B1/en not_active Expired - Lifetime
- 2000-06-08 PT PT06009072T patent/PT1686113E/pt unknown
- 2000-06-08 CN CNA2008100096668A patent/CN101245058A/zh active Pending
- 2000-06-08 SI SI200030872T patent/SI1194404T1/sl unknown
- 2000-06-08 CO CO00042752A patent/CO5160337A1/es unknown
- 2000-06-08 TR TR2006/03871T patent/TR200603871T2/xx unknown
- 2000-06-08 KR KR1020017016293A patent/KR100762188B1/ko not_active IP Right Cessation
- 2000-06-08 DK DK06009072.7T patent/DK1686113T3/da active
- 2000-06-08 NZ NZ516003A patent/NZ516003A/xx not_active IP Right Cessation
- 2000-06-08 MY MYPI20002595A patent/MY137777A/en unknown
- 2000-06-08 EP EP06009072A patent/EP1686113B1/en not_active Expired - Lifetime
- 2000-06-08 ES ES06009072T patent/ES2375823T3/es not_active Expired - Lifetime
- 2000-06-08 TR TR2002/02528T patent/TR200202528T2/xx unknown
- 2000-06-08 DE DE60027722T patent/DE60027722T2/de not_active Expired - Lifetime
- 2000-06-08 TN TNTNSN00129A patent/TNSN00129A1/fr unknown
- 2000-06-08 HU HU0300385A patent/HUP0300385A3/hu unknown
- 2000-06-08 TW TW096138754A patent/TWI318116B/zh not_active IP Right Cessation
- 2000-06-08 CZ CZ20014431A patent/CZ303052B6/cs not_active IP Right Cessation
- 2000-06-08 AT AT06009072T patent/ATE534622T1/de active
- 2000-06-08 BR BR0011745-5A patent/BR0011745A/pt not_active Application Discontinuation
- 2000-06-08 CN CNB008104395A patent/CN100516034C/zh not_active Expired - Fee Related
- 2000-06-08 IL IL14691800A patent/IL146918A0/xx unknown
- 2000-06-08 ES ES00941279T patent/ES2263478T3/es not_active Expired - Lifetime
- 2000-06-08 PT PT00941279T patent/PT1194404E/pt unknown
- 2000-06-08 AT AT00941279T patent/ATE325091T1/de active
- 2000-06-08 MX MXPA01012808A patent/MXPA01012808A/es active IP Right Grant
- 2000-06-08 TW TW093114799A patent/TWI299000B/zh not_active IP Right Cessation
- 2000-06-08 AU AU56006/00A patent/AU779994B2/en not_active Ceased
-
2001
- 2001-12-04 IL IL146918A patent/IL146918A/en not_active IP Right Cessation
- 2001-12-10 NO NO20016034A patent/NO323951B1/no not_active IP Right Cessation
- 2001-12-11 ZA ZA200110177A patent/ZA200110177B/en unknown
-
2002
- 2002-09-23 HK HK02106939.9A patent/HK1046899B/zh not_active IP Right Cessation
-
2008
- 2008-09-08 JP JP2008230351A patent/JP2009046493A/ja not_active Withdrawn
-
2009
- 2009-12-09 IL IL202633A patent/IL202633A/en not_active IP Right Cessation
-
2012
- 2012-02-22 CY CY20121100182T patent/CY1112632T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20010230A1 (es) | Sulfonamidas como inhibidores de aspartil proteasa | |
PE20030857A1 (es) | Compuestos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c | |
CO5680403A2 (es) | Antagonistas de mchr1r | |
PE46899A1 (es) | Derivados de n-fenil-sulfonamida | |
AR039669A1 (es) | Derivados de (1,4) diazepino (6,7,1/j) quinolina como agentes antipsicoticos y antiobesidad | |
PE20030762A1 (es) | Compuestos heterociclicos como antagonistas nk1 | |
PE20040479A1 (es) | Inhibidores de proteasa del vih y composiciones que los contienen | |
ES2192081T3 (es) | Derivados de purina antivirales. | |
PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
AR043466A1 (es) | Proceso de un solo paso para la preparacion de derivados anticonvulsivos | |
CO5721000A2 (es) | (tiazol-2-il)-amida o sulfonamida substituida como activado- res de glicocinasa utiles en el tratamiento de diabetes de tipo 2 | |
AR040773A1 (es) | Pirazoles utiles como inhibidores de gsk-3 | |
KR880013937A (ko) | 옥세타노신 유도체 | |
PE20020228A1 (es) | Compuestos organicos como inhibidores de 3',5' guanosin monofosfato ciclico fosfodiesterasa | |
AR044294A1 (es) | N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa | |
AR049489A1 (es) | Avermectina y monosacarido de avermectina sustituido en la posicion 4 '' y 4' respectivamente. procesos de obtencion y composiciones pesticidas | |
PE20020750A1 (es) | Derivados de pirazol | |
AR039670A1 (es) | Derivados de 1,2,3,4,7,8-hexahidro-6h-[1,4] diazepino [6,7,1j] quinolina como agentes antipsicoticos y antiobesidad | |
AR036682A1 (es) | Amidas heterociclicas, procedimiento para su preparacion, agentes que los contienen y su utilizacion | |
CO5590963A2 (es) | Derivados de avermectina b1 que tienen un substituyente de aminosulfoniloxilo en la posicion 4 | |
AR054102A1 (es) | Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas | |
PE20221586A1 (es) | Derivados heterociclicos activos como plaguicidas con sustituyentes que contienen azufre | |
DK1320526T3 (da) | Farmaceutisk aktive benzsulfonamidderivater som inhibitorer af protein-junkinaser | |
PE20220252A1 (es) | Compuestos de pirrol | |
EA200000787A1 (ru) | Промежуточные соединения для получения ациклических нуклеозидов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |